Keywords: Biodel, Linjeta, Diabetes

Biodel reports new findings from key programs for its diabetes drug candidate Linjeta

Article | 15 November 2010

Scientists from USA-based specialty pharmaceutical firm Biodel (Nasdaq: BIOD) reported new findings from the company's Linjeta, (insulin glargine), "smart" basal ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Biodel

Go to company listing

Related Drugs

Linjeta

Go to drug listing